Irritable Bowel Syndrome (IBS) Treatment Market Report 2026

Irritable Bowel Syndrome (IBS) Treatment Market Overview

• Irritable Bowel Syndrome (IBS) Treatment market size has reached to $7.41 billion in 2025 • Expected to grow to $10.65 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Prevalence Of IBS Fueling The Growth Of The Market Due To Expanding Patient Population And Awareness • Market Trend: Integration of Digital Therapeutics to Enhance Patient-Centric Gastrointestinal Care • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Irritable Bowel Syndrome (IBS) Treatment Market?

Irritable bowel syndrome (IBS) treatment refers to the various approaches and interventions aimed at treating gastrointestinal tract disorders, which are frequent disorders that affect the stomach and intestines. It is used to alleviate constipation, diarrhea, and abdominal symptoms, minimize the frequency and severity of flare-ups, and enhance overall well-being. The main types of irritable bowel syndrome (IBS) treatment drugs are lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. Lubiprostone is a medication used in the treatment of irritable bowel syndrome (IBS), and it is a selective chloride channel activator that helps to increase fluid secretion in the intestines. The various indications include IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. These are sold through several types of distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, to various end-users, including hospitals, clinics, and home care settings.

What Is The Irritable Bowel Syndrome (IBS) Treatment Market Growth Forecast?

The irritable bowel syndrome (ibs) treatment market size is expected to see strong growth in the next few years. It will grow to $10.65 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancement in precision medicine, increasing adoption of digital health platforms, growth in online pharmacy channels, rising focus on microbiome research, increasing healthcare expenditure on chronic conditions. Major trends in the forecast period include precision medicine and microbiome-based therapies, digital therapeutics and mobile health integration, AI-driven ibs diagnosis and treatment optimization, remote patient monitoring and smart gut health devices, sustainable and patient-centric drug development.

Global Irritable Bowel Syndrome (IBS) Treatment Market Segmentation

1) By Drug Type: Eluxadoline, Alosetron, Other Drugs 2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies 4) By End-Users: Hospitals, Clinics, Homecare Settings Subsegments: 1) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment, Moderate IBS-D Treatment 2) By Alosetron: Severe IBS-D Treatment for Women, Refractory IBS-D Treatment 3) By Other Drugs: Prucalopride, Tenapanor, Plecanatide

What Is The Driver Of The Irritable Bowel Syndrome (IBS) Treatment Market?

The rising prevalence of IBS is expected to propel the growth of the IBS treatment market going forward. Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder affecting the large intestine, causing symptoms such as constipation, diarrhea, abdominal pain, and bloating, and significantly impacting quality of life. The increase in IBS prevalence is due to lifestyle factors, including poor diet, stress, and environmental exposures, which contribute to more individuals developing the disorder. The IBS treatment market supports patient needs by providing both pharmacological therapies, such as antispasmodics and gut-targeted medications, and non-pharmacological interventions, including cognitive behavioral therapy, hypnotherapy, and dietary management. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, reaching over 5,300 individuals with Inflammatory Bowel Disease (IBD) by 2023, this represents an increase of more than 3,000 members compared to 2022. Therefore, the rising prevalence of IBS is driving the growth of the IBS treatment market.

Key Players In The Global Irritable Bowel Syndrome (IBS) Treatment Market

Major companies operating in the irritable bowel syndrome (ibs) treatment market are Ironwood Pharmaceuticals Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson Services Inc., AstraZeneca plc, Novartis AG, Abbott Laboratories, Eli Lilly and Company, Astellas Pharma Inc., Bausch Health Companies Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc., Salix Pharmaceuticals Ltd., Allergan plc, Synergy Pharmaceuticals Inc.

Global Irritable Bowel Syndrome (IBS) Treatment Market Trends and Insights

Major companies operating in the irritable bowel syndrome (IBS) treatment market are focusing on incorporating digital therapeutics such as gut-directed hypnotherapy–based mobile applications to enhance patient engagement, treatment accessibility, and symptom management. Gut-directed hypnotherapy–based mobile applications are prescription digital platforms that deliver structured hypnotherapy sessions through a smartphone interface to modulate gut–brain interaction, enabling capabilities such as guided behavioural therapy, real-time symptom tracking, and automated patient-progress monitoring. For instance, in May 2023, Launchit DTx, a Canada-based digital health commercialization company, launched Regulora, a gut-directed hypnotherapy–based digital therapeutic designed to help adults manage abdominal pain associated with irritable bowel syndrome (IBS), featuring evidence-based hypnotherapy modules, clinician-enabled prescribing workflows, and a mobile app that tracks patient response over time. Regulora improves treatment access, self-management, and overall symptom relief for IBS patients by offering a non-pharmacologic, digitally delivered therapeutic option.

What Are Latest Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market?

In October 2023, Roche, a Switzerland-based healthcare company acquired Telavant Holdings for an undisclosed amount. Through the acquisition, Roche will obtain the rights to develop, manufacture, and market a novel treatment for Irritable Bowel Syndrome (IBS) in the United States and Japan. Telavant Holdings is a US-based biotechnology company focusing on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases.

Regional Outlook

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Irritable Bowel Syndrome (IBS) Treatment Market?

The irritable bowel syndrome (IBS) treatment market includes revenues earned by entities by providing services such as consultation, cognitive-behavioral therapy (CBT), hypnotherapy, psychological therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The irritable bowel syndrome (IBS) market also includes sales of antispasmodics, fiber supplements, laxatives, probiotics, and certain medications targeting gut function. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Irritable Bowel Syndrome (IBS) Treatment Market Report 2026?

The irritable bowel syndrome (ibs) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the irritable bowel syndrome (ibs) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.